Trading Statement

AI SummaryClose X

SkinBioTherapeutics plc announced that Rachel Parsonage and Alyson Levett will transition to permanent CEO and Non-Executive Chair roles, respectively. The company expects full-year revenue for the period ended 30 June 2026 to grow approximately 20.5% to £4.7 million, driven by Bio-Tech Solutions contributing £2.1 million. The adjusted EBITDA loss is projected at £1.6 million, with £1.2 million in exceptional costs related to an investigation. Cash reserves stood at £1.5 million as of 30 June 2026, and early FY27 trading has exceeded expectations.

Disclaimer*

UK 100

Latest directors dealings